Recent Updates
Recently added Catalysts

VXCO-102

Phase 1

EBV | Biologics | Other |Eli Lilly and Company|Trials Updated: Oct 26, 2026

VXCO-102 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Apr 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment82

FDA Designations

No designations recorded

VXCO-102 clinical trials

VXCO-102 · 1 trial · 1 indication

Phase 1 1
NCT07557602mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsEBV
RECRUITING82 Analytics
PHASE1RECRUITING
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
EBVUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Solicited Local and Systemic Reactions
7 days after each product administration
Number of Participants with Unsolicited Adverse Events
Up to 28 days after each product administration
Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs)
Day 1 to end of study (Day 357)

Secondary Endpoints

Rate and Magnitude of Neutralizing Antibody Responses
Day 1 and 85
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group 1EXPERIMENTALDose 1 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Group 2EXPERIMENTALDose 2 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
Group 3EXPERIMENTALDose 3 - VXCO-102 administered IM by needle and syringe at Day 1 and Week 8
PlaceboPLACEBO_COMPARATORSodium Chloride administered IM by needle and syringe at Day 1 and Week 8

Interventions

NameTypeDescription
VXCO-102BIOLOGICALSterile liquid for injection
PlaceboBIOLOGICAL0.9% sodium chloride (BP grade)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 25 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that ...

Countries:Australia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 26, 2026NCT07557602Status: NOT_YET_RECRUITING → RECRUITING
MEDIUMOct 26, 2026NCT07557602Status: NOT_YET_RECRUITING → RECRUITING

Frequently asked questions about VXCO-102

What is VXCO-102?

VXCO-102 is an investigational monoclonal antibody being developed by Eli Lilly and Company for Epstein-Barr virus, or EBV. It is in Phase 1 clinical development. It is a biologic therapy rather than a small molecule, and it is being studied in a single recruiting clinical trial.

What is VXCO-102 used for in EBV?

VXCO-102 is being developed for Epstein-Barr virus (EBV) infection. Its only listed clinical program is a Phase 1 study in EBV. Because the program is at the Phase 1 stage, VXCO-102 remains investigational and has not been established as a treatment for any condition.

Who makes VXCO-102?

VXCO-102 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 program for the monoclonal antibody in Epstein-Barr virus.

What phase is VXCO-102 in?

VXCO-102 is in Phase 1 clinical development. It is investigational and is not approved for any indication. The program consists of one Phase 1 trial that is currently recruiting, with no completed trials reported.

What clinical trials is VXCO-102 in?

VXCO-102 is being studied in trial NCT07557602, a Phase 1 study titled mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults. The trial is recruiting in Australia, is randomized, double-blind, and placebo-controlled, and plans to enroll 82 participants aged 18 years and older.

Is VXCO-102 given to healthy volunteers?

Yes. The Phase 1 trial of VXCO-102, NCT07557602, enrolls healthy volunteers rather than patients with an active disease. Participants must be at least 18 years old, and the study accepts all sexes. The trial is placebo-controlled, randomized, and double-blind, with planned enrollment of 82.